SD BIOSENSOR STANDARD F COVID-19 and COVID/FLU A&B pathogens
The STANDARD F COVID-19 and STANDARD F COVID/Flu Ag Combo FIA are fluorescent immunoassays for the qualitative detection of specific
antigens to SARS-CoV-2 and Influenza A & B. The COVID/FLU test is a
differentiated test, such that SARS-CoV-2 viral antigens can be
distinguished from Influenza A or Influenza B viral antigens from a
single specimen using a single device.
The tests are used with the STANDARD F Analyzers manufactured by SD BIOSENSOR.
Generally
The SD BIOSENSOR STANDARD F COVID-19 antigen test and COVID/Flu Ag Combo FIA are intended as an aid to early diagnosis of SARS-CoV-2 and for Influenza A and Influenza B.
The tests are for administration by healthcare workers and labs only, as an aid to early diagnosis of SARS-CoV-2, Influenza A or Influenza B infection in patient with clinical symptoms with viral infection. It provides only an initial screening test result. More specific alternative diagnosis methods should be performed in order to obtain the confirmation of SARS-CoV-2, Influenza A or Influenza B infection.
SD BIOSENSOR STANDARD F COVID-19 kits provide
- Ease of use
- Safe handling of the kit
- Excellent performance
- Fast and flexible result
- Evaluated and found on the Paul-Ehrlich Institute list of reimbursed tests as well as on the EU common list of antigen tests
About the analyte
Influenza virus and SARS-CoV-2 both have a similar disease presentation. They both cause respiratory disease, which presents as a wide range of illness from asymptomatic or mild through to severe disease and death. Both viruses are transmitted by contact, droplets and fomites. As of May 2020, clinical trials of COVID-19 and more than 20 vaccines are being developed in China, but there are currently no licensed vaccines for SARS-CoV-2, but influenza has both vaccines and medications. STANDARD F COVID/Flu Ag Combo FIA, containing a highly specific and sensitive antibody to SARS-CoV-2, Influenza A and Influenza B, provides significantly fast, easy and accurate system to identify the target antigen in an extraction from nasal and nasopharyngeal swab specimens. The test is the reliable clinical diagnosis of SARS-CoV-2 or influenza A/B and enables supportive clinical decisions.